dars-1 Antibody

What is DARS-1 antibody and what cellular functions does it help investigate?

DARS-1 antibody targets aspartyl-tRNA synthetase (DARS), a crucial enzyme involved in protein synthesis that catalyzes the attachment of aspartic acid to its cognate tRNA. This antibody enables researchers to investigate fundamental cellular translation mechanisms, protein synthesis regulation, and related pathways . Methodologically, DARS-1 antibody detection requires careful consideration of sample preparation techniques that preserve protein structure while maximizing epitope accessibility. When designing experiments, researchers should account for the subcellular localization of DARS, which predominantly shows cytoplasmic distribution with potential additional compartmentalization depending on cell type and physiological conditions.

Which experimental applications are validated for DARS-1 antibody?

DARS-1 antibody has been validated for multiple experimental applications including Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), Co-Immunoprecipitation (CoIP), and ELISA . Each application requires specific optimization protocols and dilution ratios. For Western blotting, the recommended dilution ranges from 1:2000 to 1:10000, while immunohistochemistry applications typically use 1:1000 to 1:4000 dilutions . For immunoprecipitation, researchers should use 0.5-4.0 μg of antibody per 1.0-3.0 mg of total protein lysate to achieve optimal results . Cross-application validation is recommended when transitioning between different experimental platforms to ensure consistent target recognition.

What species reactivity has been confirmed for DARS-1 antibody?

Current evidence demonstrates that DARS-1 antibody (specifically product 14989-1-AP) shows confirmed reactivity with human, mouse, and rat samples . Cross-reactivity analyses have established consistent detection across these mammalian models, making it suitable for comparative studies. When working with novel or untested species, preliminary validation experiments are strongly recommended, particularly through Western blot to confirm appropriate molecular weight detection and specificity.

What are the optimal conditions for Western blot detection using DARS-1 antibody?

For Western blot applications, DARS-1 antibody has been validated to detect protein bands at 50-57 kDa, corresponding to the calculated molecular weight of 57 kDa for the DARS protein . Optimization strategies should include:

• Sample preparation with appropriate lysis buffers containing protease inhibitors

• Protein loading optimization (typically 20-50 μg total protein)

• Dilution testing within the recommended 1:2000-1:10000 range

• Incubation time and temperature adjustments (typically overnight at 4°C)

• Blocking optimization to minimize background

Positive control samples should include HeLa, MCF-7, or K-562 cell lysates, which have been confirmed to express detectable levels of DARS protein .

What protocol modifications are necessary for successful immunohistochemistry with DARS-1 antibody?

For IHC applications, DARS-1 antibody requires specific antigen retrieval conditions for optimal results. Data suggests using TE buffer at pH 9.0 for antigen retrieval, although citrate buffer at pH 6.0 may serve as an alternative . The following protocol adjustments are critical:

• Tissue fixation should be optimized (10% neutral buffered formalin for 24-48 hours)

• Section thickness of 4-6 μm is recommended

• Use dilutions between 1:1000-1:4000 based on tissue type

• Incorporate positive control tissues (rat brain tissue has been validated)

• Include negative controls (primary antibody omission and isotype controls)

Researchers should also be aware that excessive antigen retrieval can damage tissue morphology, while insufficient retrieval may yield false-negative results, necessitating careful protocol optimization.

How should researchers troubleshoot non-specific binding when using DARS-1 antibody?

Non-specific binding is a common challenge when working with antibodies. For DARS-1 specifically, researchers should consider:

• Increasing blocking agent concentration (5% BSA or 5% non-fat dry milk)

• Incorporating additional washing steps with increased detergent concentration

• Titrating antibody concentration systematically across the recommended dilution range

• Pre-adsorption tests with recombinant DARS protein to confirm specificity

• Testing multiple secondary antibody options and concentrations

Cross-reactivity assessment should be performed, particularly in complex samples where similar synthetases may be present. Western blot analysis with knockout or knockdown controls provides definitive specificity confirmation when available.

How can DARS-1 antibody be utilized in co-immunoprecipitation studies to investigate protein-protein interactions?

For co-immunoprecipitation (CoIP) applications, DARS-1 antibody has been successfully employed to investigate protein-protein interactions involving aspartyl-tRNA synthetase . The methodological approach should include:

• Cell lysis under non-denaturing conditions to preserve protein complexes

• Pre-clearing of lysates with appropriate control IgG

• Antibody immobilization on protein A/G beads

• Optimization of binding and washing conditions

• Careful elution and analysis of precipitated complexes

Researchers should be aware that the affinity and specificity of DARS-1 antibody in CoIP applications may differ from Western blot applications due to tertiary structure recognition. Crosslinking techniques may be necessary for transient interactions, and reciprocal CoIPs (pulling down with interacting partner antibodies) should be performed to confirm results.

What role does DARS-1/DARS1-AS1 play in cancer research applications?

Recent research has identified DARS1-AS1 (antisense RNA related to DARS1) as a significant factor in glioblastoma tumorigenesis and radioresistance . DARS1-AS1 appears to interact with YBX1 to promote target mRNA binding and stabilization, forming a transcriptional/posttranscriptional feed-forward loop that regulates G1-S cell cycle transition . Experimental considerations when investigating this pathway include:

• Cell model selection (validated in GBM cell lines U251, U87, LN229 and patient-derived GSCs)

• RNA interference approaches (shRNA-mediated depletion shows efficacy)

• Functional readouts (proliferation assays, self-renewal assays for GSCs)

• In vivo validation (orthotopic tumor models show survival extension with DARS1-AS1 depletion)

The research methodology should incorporate RNA-protein interaction assays such as RNA immunoprecipitation (RIP) or crosslinking immunoprecipitation (CLIP) to validate the DARS1-AS1/YBX1 interaction, combined with mRNA stability assays to confirm the posttranscriptional regulatory mechanism .

What are the considerations for investigating DARS-1 in the context of homologous recombination DNA repair mechanisms?

Evidence suggests DARS1-AS1 depletion impairs homologous recombination (HR)-mediated double-strand break (DSB) repair . When investigating this aspect, researchers should consider:

• Implementation of DNA damage assays (γH2AX foci formation)

• HR repair pathway activity measurements

• Assessment of key DNA repair proteins (including FOXM1)

• Radiation sensitivity testing across dose ranges

• Time-course analyses to capture repair kinetics

Methodologically, combining DARS-1 antibody with antibodies against DNA repair proteins in co-localization studies can provide spatial and temporal information about DARS's potential role in DNA repair complexes. Functional assays such as reporter constructs measuring HR efficiency should be incorporated to quantitatively assess repair capacity under DARS modulation.

How can researchers validate DARS-1 antibody specificity for their experimental systems?

Antibody validation is crucial for experimental reliability. For DARS-1 antibody, a comprehensive validation approach should include:

This multi-dimensional approach significantly increases confidence in antibody specificity and reduces the risk of misleading results due to cross-reactivity or non-specific binding .

What are the considerations for dual immunofluorescence studies involving DARS-1 antibody?

When designing dual immunofluorescence experiments with DARS-1 antibody, researchers must address several technical challenges:

• Primary antibody compatibility (different species origin to avoid cross-reactivity)

• Fluorophore selection to minimize spectral overlap

• Sequential versus simultaneous antibody incubation optimization

• Appropriate controls (single staining controls, isotype controls, absorption controls)

• Imaging parameters optimization (exposure, gain, offset)

For co-localization studies with potential interaction partners such as YBX1 or FOXM1, super-resolution microscopy techniques may be necessary to accurately assess spatial relationships at the subcellular level . Quantitative co-localization analysis should employ established statistical methods like Pearson's or Mander's coefficients.

How can DARS-1 antibody be incorporated into multiplexed proteomic analysis workflows?

For researchers interested in more comprehensive proteomic approaches, DARS-1 antibody can be incorporated into multiplexed analysis using:

• Sequential immunoblotting with stripping and reprobing

• Multiplexed immunofluorescence using antibodies from different species

• Mass spectrometry-based approaches following immunoprecipitation

• Protein array technologies for interaction screening

• Single-cell proteomic approaches for heterogeneity assessment

When designing multiplexed approaches, careful attention must be paid to potential antibody cross-reactivity, signal spillover, and quantification challenges. For mass spectrometry applications following DARS-1 immunoprecipitation, specialized sample preparation protocols may be required to minimize contamination with antibody fragments and maximize capture of transient interaction partners.

How does DARS-1 antibody compare to other tRNA synthetase antibodies for studying multi-synthetase complexes?

Aminoacyl-tRNA synthetases, including DARS, often function in multi-synthetase complexes (MSCs) with additional non-catalytic functions. When investigating these complexes:

• Compare DARS-1 antibody with antibodies against other MSC components

• Employ blue native PAGE to preserve complex integrity

• Use gradient gel systems to resolve high molecular weight complexes

• Consider chemical crosslinking to stabilize transient interactions

• Implement proximity labeling approaches (BioID, APEX) to capture interaction networks

Methodologically, researchers should validate that the DARS-1 antibody epitope is accessible in the context of the intact MSC, as conformational changes or protein-protein interactions may mask binding sites in the native complex compared to denatured Western blot applications.

What are the methodological considerations for studying DARS-1 in relation to antibody-drug conjugates (ADCs)?

While not directly related to DARS-1 antibody, the search results contained information about antibody-drug conjugates (ADCs) with drug-to-antibody ratios (DAR) of 1 (DAR1) . Researchers interested in the broader field of antibodies as therapeutic tools should consider:

• Site-specific conjugation strategies without antibody re-engineering

• Homogeneity assessment through RP-UPLC and MS analysis

• Payload adaptability with various linker-drug combinations

• In vitro efficacy testing in appropriate cell line models

• Tumor penetration assessment through spheroid models

The technology for generating homogeneous DAR1 ADCs may be particularly valuable for antibodies conjugated to ultrapotent payloads, as demonstrated by comparative studies showing only 1.5-2.4 fold differences in potency between DAR1 and DAR2 constructs despite the 2-fold payload difference .

How can researchers apply machine learning approaches to enhance antibody-based detection methods?

Emerging technologies are combining antibody-based detection with computational approaches. For example, machine learning has been applied to visual auditing of lateral flow immunoassays for SARS-CoV-2 antibodies . Similar approaches could be developed for quantitative analysis of DARS-1 antibody signals in various applications:

• Automated Western blot band quantification with noise reduction

• Pattern recognition in immunohistochemistry/immunofluorescence images

• Prediction of antibody performance across experimental conditions

• Multi-parameter optimization of antibody-based protocols

• Quality control automation for antibody validation

These computational approaches can help standardize antibody-based methods, reduce subjective interpretation, and potentially identify subtle patterns in data that might be missed in manual analysis .